CD20单抗-话题@MedSci - 梅斯（MedSci）

#CD20单抗#

15篇内容 | 1324人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1581398, encodeId=618b158139825, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=全人源CD20单抗！诺华多发性硬化新药奥法妥木单抗在中国获批, objectType=article, longId=292522, objectId=095329252292, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=095329252292, replyNumber=0, likeNumber=85, createdTime=2021-12-24, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=095329252292, moduleTitle=全人源CD20单抗！诺华多发性硬化新药奥法妥木单抗在中国获批, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=095329252292)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581397, encodeId=bc02158139edc, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=JNNP：抗CD20单抗疗法降低多发性硬化症或视神经脊髓炎患者对SARS-CoV-2的体液免疫应答, objectType=article, longId=215532, objectId=d6f5215532da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6f5215532da, replyNumber=0, likeNumber=56, createdTime=2021-08-11, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6f5215532da, moduleTitle=JNNP：抗CD20单抗疗法降低多发性硬化症或视神经脊髓炎患者对SARS-CoV-2的体液免疫应答, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d6f5215532da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581396, encodeId=dad71581396b9, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, objectType=article, longId=202384, objectId=f40b202384ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f40b202384ce, replyNumber=0, likeNumber=53, createdTime=2020-10-24, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f40b202384ce, moduleTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f40b202384ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581395, encodeId=dd1d1581395e4, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=Lancet Haematol：CD20单抗Obinutuzumab联合DHAP治疗套细胞淋巴瘤的疗效, objectType=article, longId=201580, objectId=a894201580eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a894201580eb, replyNumber=0, likeNumber=65, createdTime=2020-10-05, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a894201580eb, moduleTitle=Lancet Haematol：CD20单抗Obinutuzumab联合DHAP治疗套细胞淋巴瘤的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a894201580eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581394, encodeId=0114158139452, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=滤泡性淋巴瘤一线治疗将有新标准！新一代抗CD20单抗佳罗华®中国获批, objectType=article, longId=194365, objectId=0d90194365fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d90194365fe, replyNumber=0, likeNumber=0, createdTime=2020-05-20, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d90194365fe, moduleTitle=滤泡性淋巴瘤一线治疗将有新标准！新一代抗CD20单抗佳罗华®中国获批, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0d90194365fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581393, encodeId=3c031581393aa, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=抗CD20单抗科普：从一代的利妥昔到三代的阿妥珠 , objectType=article, longId=193743, objectId=df92193e4370, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df92193e4370, replyNumber=0, likeNumber=125, createdTime=2020-05-09, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df92193e4370, moduleTitle=抗CD20单抗科普：从一代的利妥昔到三代的阿妥珠 , moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=df92193e4370)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581392, encodeId=56ab1581392ae, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者, objectType=article, longId=193606, objectId=c7931936061f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7931936061f, replyNumber=0, likeNumber=46, createdTime=2020-05-08, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7931936061f, moduleTitle=加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c7931936061f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581391, encodeId=7cd3158139162, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, objectType=article, longId=190017, objectId=0f0519001e6d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f0519001e6d, replyNumber=0, likeNumber=45, createdTime=2020-03-16, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f0519001e6d, moduleTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0f0519001e6d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581390, encodeId=a2751581390fe, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, objectType=article, longId=187245, objectId=3b7518e245e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b7518e245e4, replyNumber=0, likeNumber=71, createdTime=2020-02-04, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b7518e245e4, moduleTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3b7518e245e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581389, encodeId=2346158138909, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=FDA授予罗氏的CD20单抗Gazyva在狼疮性肾炎中的突破性治疗指定, objectType=article, longId=179673, objectId=1fca1e96732d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fca1e96732d, replyNumber=0, likeNumber=0, createdTime=2019-09-20, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fca1e96732d, moduleTitle=FDA授予罗氏的CD20单抗Gazyva在狼疮性肾炎中的突破性治疗指定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1fca1e96732d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581388, encodeId=1a8f1581388ab, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功, objectType=article, longId=178542, objectId=bc501e854207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc501e854207, replyNumber=0, likeNumber=139, createdTime=2019-09-03, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc501e854207, moduleTitle=诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bc501e854207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581387, encodeId=1260158138e67, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=2019年欧洲神经病学学会（EAN）：CD20单抗Ublituximab治疗复发多发性硬化患者安全、耐受良好, objectType=article, longId=174977, objectId=d4a81e497768, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4a81e497768, replyNumber=0, likeNumber=61, createdTime=2019-07-09, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4a81e497768, moduleTitle=2019年欧洲神经病学学会（EAN）：CD20单抗Ublituximab治疗复发多发性硬化患者安全、耐受良好, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d4a81e497768)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581386, encodeId=fa26158138652, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=CD20单抗在淋巴瘤治疗中仍是基石药物, objectType=article, longId=168976, objectId=dfee1689e6f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfee1689e6f2, replyNumber=0, likeNumber=72, createdTime=2019-06-24, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfee1689e6f2, moduleTitle=CD20单抗在淋巴瘤治疗中仍是基石药物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dfee1689e6f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581385, encodeId=46af158138575, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=罗氏的抗CD20单抗ocrelizumab在英国获批上市，治疗原发性进行性多发性硬化症, objectType=article, longId=165885, objectId=92ae165885e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92ae165885e9, replyNumber=0, likeNumber=76, createdTime=2019-05-13, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92ae165885e9, moduleTitle=罗氏的抗CD20单抗ocrelizumab在英国获批上市，治疗原发性进行性多发性硬化症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=92ae165885e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581384, encodeId=2fca158138448, content=<a href='/topic/show?id=29e042919d' target=_blank style='color:#2F92EE;'>#CD20单抗#</a>, objectTitle=新研究显示BCL2抑制剂联合CD20单抗治疗慢性淋巴细胞白血病，缓解率达95%, objectType=article, longId=164498, objectId=282016449820, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282016449820, replyNumber=0, likeNumber=80, createdTime=2019-04-19, rootId=0, userName=ms8888626721583891, userId=d3f716785352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282016449820, moduleTitle=新研究显示BCL2抑制剂联合CD20单抗治疗慢性淋巴细胞白血病，缓解率达95%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=282016449820)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CD20单抗

2020-05-29

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

全人源CD20单抗！诺华多发性硬化新药奥法妥木单抗在中国获批

2021-12-24

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

JNNP：抗CD20单抗疗法降低多发性硬化症或视神经脊髓炎患者对SARS-CoV-2的体液免疫应答

2021-08-11

智者为医08 (审核中...)

前往app查看评论内容

#CD20单抗#

CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定

2020-10-24

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

Lancet Haematol：CD20单抗Obinutuzumab联合DHAP治疗套细胞淋巴瘤的疗效

2020-10-05

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

滤泡性淋巴瘤一线治疗将有新标准！新一代抗CD20单抗佳罗华®中国获批

2020-05-20

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

抗CD20单抗科普：从一代的利妥昔到三代的阿妥珠

2020-05-09

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者

2020-05-08

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病

2020-03-16

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价

2020-02-04

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

FDA授予罗氏的CD20单抗Gazyva在狼疮性肾炎中的突破性治疗指定

2019-09-20

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功

2019-09-03

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

2019年欧洲神经病学学会（EAN）：CD20单抗Ublituximab治疗复发多发性硬化患者安全、耐受良好

2019-07-09

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

CD20单抗在淋巴瘤治疗中仍是基石药物

2019-06-24

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

罗氏的抗CD20单抗ocrelizumab在英国获批上市，治疗原发性进行性多发性硬化症

2019-05-13

ms8888626721583891 (审核中...)

前往app查看评论内容

#CD20单抗#

新研究显示BCL2抑制剂联合CD20单抗治疗慢性淋巴细胞白血病，缓解率达95%

2019-04-19

科室
- - 订阅+
  - 更多科室
工具
服务